RecruitingPhase 2NCT06248606

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Sponsor

Ryan Gentzler, MD

Enrollment

30 participants

Start Date

Aug 6, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer NSCLC KRAS G12C

Summary

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a targeted drug called adagrasib combined with focused brain radiation (stereotactic radiosurgery, or SRS) for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called KRAS G12C and has spread to the brain. Adagrasib targets the KRAS G12C mutation and may also shrink brain tumors when combined with radiation. **You may be eligible if...** - You are 18 or older - You have stage IV NSCLC with a confirmed KRAS G12C mutation - You have untreated brain metastases that have not yet been treated - You are in good physical condition **You may NOT be eligible if...** - You have brain metastases that require urgent surgery - Your brain tumors are too numerous or too large for the SRS procedure - You have previously had adagrasib - You have significant heart or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.